The change to the company’s leadership has been expedited as a result of the difficult market conditions and drop in share price that the company has experienced since mid-2024.

In this interview with The Pharma Navigator, Kevin Li from BioDuro reveals what he is looking forward to most and what the company will be showcasing at this year’s CPHI Americas event.

The Pharma Navigator sits down with Mara Candido from Aenova to learn more about the one-stop-shop experience, benefits of working with an end-to-end service provider, how advanced formulation strategies can aid with bioavailability/solubility issues, and the company’s focus for this year’s CPHI Americas event.  

As demand for biologic drug substance manufacturing rises, The Pharma Navigator, chats with Carrie Bracco from Novartis Contract Manufacturing about how this trend is impacting service providers, the challenges facing CDMOs in the space, and the benefits of strategic partnerships.

In this interview with The Pharma Navigator, Dan Dobry from Bend Bioscience chats about the value of comprehensive end-to-end services, challenges and future trends for OSD CDMOs, and the company’s focus for this year’s CPHI Americas event.

The Pharma Navigator discusses the increasingly complex therapeutic landscape and how strategic partnerships can be beneficial with Dr. Srinivasan Shanmugam from Adare, and finds out more about the company’s plans for CPHI Americas with Steven Facer, Senior Vice President, Global Sales and Marketing.

As more innovators look to develop orally administered GLP-1s further demand will be placed onto CDMOs to provide the expertise and capabilities needed to support the next generation of these drugs.

As the bio/pharma industry faces the looming threat of tariffs, it is clearer than ever that reporting on the key issues and trends set to shape industry is imperative to help stakeholders stay informed.

For decades, successful pharmaceutical manufacturing has been judged on scale. Nowadays, higher precedence is being given to speed, coping with complexity, and customization.

A challenging biotech investment landscape is shaking up the industry and having a negative impact on multiple CDMOs in the space.

Over the next five years, Novartis will be investing USD23 billion in 10 facilities, including seven new facilities.

CDMO, Suven Pharmaceuticals, aims to reach USD 1 bn in revenue by 2030, by investing in new facilities to increase production capacity and strengthen its capabilities in drug development and manufacturing to support global pharmaceutical clients.

CDMO partnerships are great when they are successful, but what happens when they falter? The complexity of modern outsourcing partnerships means that failure is often costly, with consequences that can ripple across timelines, budgets, and reputations.

Indian CDMO, Shilpa Medicare, has launched a 'hybrid' CDMO model at DCAT 2025. Focusing on oncology, the company will begin to offer both traditional CDMO services and ready-to-license novel formulations, allowing clients to leverage Shilpa's expertise without development risks or delays.

Florida-based CDMO, GBI Biomanufacturing (GBI), has announced the appointment of Sven Lee to its board of directors. Mr. Lee brings decades of global experience in the biologics CDMO sector, having held executive and board positions at companies such as Abzena, Catalent, and Biocina, with expertise encompassing strategic growth, marketing, commercialization, licensing, and innovation in drug development.

Biopharma companies are increasingly dependent on CDMOs to streamline production, enhance efficiency, and accelerate drug development. As therapies become more complex and regulatory demands grow, the ability to outsource manufacturing to a trusted partner has never been more essential.

Catalent has appointed Susan Mahony (formerly of Eli Lilly), Marie-France Tschudin (ex-Novartis executive), and Tim Walbert (CEO of Horizon Therapeutics) to its Board of Directors as the company looks to strengthen its position as an independent CDMO under Novo Holdings' ownership.

Vertex Pharmaceuticals has ended its 2022 research collaboration with Verve Therapeutics, set up to develop an in vivo gene editing program for a specific liver disease. The decision, attributed to Vertex's shifting research priorities, allows Verve to regain full rights to the program.

Leading CDMO, Alcami, has announced the appointment of Tori E. Arens as President of Drug Product. With over 25 years’ experience in pharmaceutical manufacturing, Arens will oversee Alcami's cGMP drug product manufacturing operations, including sterile fill-finish facilities in North and South Carolina, as well as oral solid dose manufacturing, packaging, and labeling in North Carolina.

DNA CDMO, Touchlight, has appointed Will Downie as a key adviser to advance its genetic medicine initiatives. Downie brings 30+ years’ experience in the pharmaceutical and biotech sectors, having previously served as CEO of Argenta and Vectura Group, and before that as Senior VP and Chief Commercial Officer at Catalent.